Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renin inhibition

H D Kleinert1

  • 1Abbott Laboratories, Abbott Park, IL 60064, USA.

Cardiovascular Drugs and Therapy
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

Renin inhibitors offer a promising alternative for cardiovascular disease treatment by effectively lowering blood pressure. Further development is warranted for these compounds, which show sustained effects and beneficial cardiovascular outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion.

The American journal of cardiology·1999
Same author

Renin inhibitors.

Pharmaceutical biotechnology·1998
Same author

Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging.

Neurology·1998
Same author

Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·1997
Same author

Hemodynamic effects of renin inhibitors.

American journal of nephrology·1996
Same author

Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist.

Advances in experimental medicine and biology·1996
Same journal

Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).

Cardiovascular drugs and therapy·2026
Same journal

Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Impact of Nitric Oxide Metabolites On Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG: an Exploratory Observational Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

Cardiovascular drugs and therapy·2026
Same journal

Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.

Cardiovascular drugs and therapy·2026
Same journal

Shenfu Injection Inhibits Cardiac Fibroblast Activation and Improves Myocardial Fibrosis by Down-regulating M1 Macrophage-Derived Exosomal miR-155-5p.

Cardiovascular drugs and therapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in cardiovascular regulation.
  • Current treatments like angiotensin-converting enzyme (ACE) inhibitors target the RAAS.
  • Renin inhibitors present a potential alternative therapeutic strategy for cardiovascular diseases.

Purpose of the Study:

  • To evaluate the potential of renin inhibitors as an alternative to ACE inhibitors for cardiovascular disease treatment.
  • To address the challenges in developing orally bioavailable and pharmacologically stable renin inhibitors.
  • To assess the efficacy and safety of renin inhibitors in preclinical and clinical settings.

Main Methods:

  • Development of peptidomimetic renin inhibitors with enhanced stability against enzymatic degradation.

Related Experiment Videos

  • Optimization of physical characteristics to improve intestinal absorption for oral bioavailability.
  • Administration of renin inhibitors in animal models to assess blood pressure reduction and cardiovascular effects.
  • Clinical studies in patients with hypertension and congestive heart failure to confirm efficacy.

    • Main Results:

    • Renin inhibitors demonstrated significant reduction in both systolic and diastolic blood pressures in animal models.
    • These blood pressure reductions were sustained with chronic administration without causing reflex tachycardia.
    • Initial clinical studies confirmed beneficial cardiovascular effects in patients with hypertension and heart failure.
    • Peptidomimetic renin inhibitors show promise due to improved oral bioavailability and stability.

    Conclusions:

    • Renin inhibitors are a viable alternative to ACE inhibitors for managing cardiovascular diseases.
    • Advancements in peptidomimetic design have overcome key challenges in renin inhibitor development.
    • Further research and development of renin inhibitors are strongly recommended for clinical application.